Arcutis Biotherapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
On June 4, 2025, Todd Franklin Watanabe, our Chief Executive Officer, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 135,000 shares of common stock held by Mr. Watanabe between October 1, 2025 and September 30, 2026.
On June 6, 2025, Masaru Matsuda, our General Counsel, entered into a Rule 10b5-1 trading plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the potential sale of up to 83,126 shares of common stock held by Mr. Matsuda between September 4, 2025 and September 4, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.